Bookmark

Add to MyYahoo RSS

Myriad Genetics News

News on Myriad Genetics (Ticker: MYGN) continually updated from thousands of sources around the net.

2 hrs ago | Local Tech Wire

Biotech patent holders: I hate to say I told you so, but ...

Editor's Note: Edward R. Ergenzinger, Ph.D., is a member of the Intellectual Property Practice Group at Ward and Smith, P.A. On March 4, 2014, the U.S. Patent and Trademark Office issued new guidelines to its Patent Examiners to assist them in determining which patent claims are not eligible for patenting.

Comment?

Related Topix: Patent / Trademark Law, Law, Biotech, Medicine, Healthcare Industry, Genetics, Rules-Based Medicine, Myriad Pharmaceuticals, US News, US Supreme Court

Mon Apr 14, 2014

AmericanBankingNews.com

Myriad Genetics Receives Neutral Rating from Bank of America

's stock had its "neutral" rating restated by stock analysts at Bank of America in a report issued on Monday, AnalystRatings.Net reports.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Genetics, Rules-Based Medicine, Myriad Pharmaceuticals

Sat Apr 12, 2014

Salt Lake Tribune

Led by Myriad Genetics, Utah health services make millions from Medicare

Myriad Genetics takes in twice as much revenue from Medicare - $54 million in 2012 - as all other laboratories and similar businesses in Utah combined, according to an analysis of federal data.

Comment?

Related Topix: Medicare, Health, Biotech, Medicine, Healthcare Industry, Genetics, Sundance Film Festival, Utah, Biology, Science

Wed Apr 09, 2014

The Motley Fool

The Nasdaq's 3 Most Hated Stocks

Since hitting highs not seen in practically 14 years, the technology- and biotechnology-heavy Nasdaq Composite has been throttled, falling more than 5% on a trailing basis from the high point reached in early March.

Comment?

Related Topix: Financial Markets, Biotech, Science / Technology, Home, Mortgage, Personal Finance, Medicine, Healthcare Industry, Medicare, Health

Mon Apr 07, 2014

GlobeNewswire

DGAP-News: Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis

News: Myriad Genetics, Inc. / Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis 07.04.2014 / 22:30 --------------------------------------------------------------------- BRACAnalysis to be Used as Companion Diagnostic for AstraZeneca's Olaparib SALT LAKE CITY, 2014-04-07 22:30 CEST -- Myriad Genetics, Inc. today announced that it ... (more)

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Healthcare Law, Law, Food and Drug Administration, Genetics, Rules-Based Medicine, Myriad Pharmaceuticals

GlobeNewswire

Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis

Myriad Genetics, Inc. today announced that it has submitted the first module of a premarket approval application to the Food and Drug Administration for the use of BRAC Analysis testing as a companion diagnostic with olaparib.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Healthcare Law, Law, Food and Drug Administration, Genetics, Rules-Based Medicine, Myriad Pharmaceuticals

The Motley Fool

The AACR Annual Meeting May Move These 2 Stocks

The American Association for Cancer Research meeting shines a bright light on gene testing like that performed by Myriad, and on promising late stage breast cancer treatments, including Pfizer's palbociclib.

Comment?

Related Topix: Medicine, Cancer, Health, Biotech, Healthcare Industry, Breast Cancer, Genetics, Biology, Science, Startups, BioMarin Pharmaceutical

Fri Apr 04, 2014

AmericanBankingNews.com

Mizuho Upgrades Myriad Genetics to "Buy"

Several other analysts have also recently commented on the stock. Analysts at Cowen and Company raised their price target on shares of Myriad Genetics from $24.00 to $37.00 in a research note on Friday.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Genetics, Rules-Based Medicine, Myriad Pharmaceuticals

Thu Apr 03, 2014

The Motley Fool

When Harsh Medicare Cuts Are Cause for Celebration

Though the cuts were harsh, they were lower than the market had been fearing, and Myriad came out on top as a result.

Comment?

Related Topix: Biotech, Healthcare Industry, Science / Technology, Inventions

Investor's Business Daily

Indexes Edge Higher; Rubicon Project Soars In Debut

The S&P 500 led the way, up 0.2%, while the Dow Jones industrial average and Nasdaq rose 0.1%.

Comment?

Related Topix: Medicaid, Health, Biotech, Medicine, Healthcare Industry

The Motley Fool

Why MannKind Corporation, Myriad Genetics, Inc., and Intuitive Surgical, Inc. are Today's 3 Best Sto

Record highs have been a daily occurrence for the markets as of late, and despite an up-and-down day, the S&P 500 wouldn't be held back from hitting new intraday marks yet again today.

Comment?

Related Topix: Startups, Intuitive Surgical, Biotech, Medicine, Healthcare Industry, Genetics, Biology, Science, Financial Markets

Wed Apr 02, 2014

TheStreet.com

Why Myriad Genetics (MYGN) Stock Hit a One-Year High Today

Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Genetics, Biology, Science, Mozilla, TheStreet

Investor's Business Daily

Myriad Gaps Up To High On Reimbursement Rate Change

Myriad surged 4.03, or 11%, to 39.18 in huge volume . The IBD 50 stock is 15% past a 34 buy point of a cup with handle it cleared Feb. 18. The Salt Lake City-based company updated its pricing for its BRAC-Analysis tests , which are used to gauge a woman's risk of developing hereditary breast or ovarian cancer.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

The Motley Fool

Why Myriad Genetics, Inc. Popped Today

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Medicare, Medicaid, Health

AmericanBankingNews.com

Myriad Genetics Price Target Increased to $33.00 by Analysts at Jefferies Group

Jefferies Group's price objective indicates a potential downside of 6.12% from the company's current price.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Genetics, Rules-Based Medicine, Myriad Pharmaceuticals, Investment Banking, Financial Services, Jefferies Group, Investment Services

Barron's

Morning Movers: MannKind Doubles on FDA Recommendation; Myriad Genetics Soars on Medicare Decision

Shares of Mannkind have gained 92% to $7.70 after an FDA panel recommended approving one of its drugs .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Apollo Group, Agrium, Chemicals

Investor's Business Daily

Jobs Data Trim Stock Futures; Myriad Genetics Spikes

Dow futures traded 11.3 points above fair market value, about half their earlier gain.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Genetics, Biology, Science, Medicaid, Health

Tue Apr 01, 2014

JD Supra

Dr. Cook-Deegan Brings the Medical Community Up to Date on the Myriad Case

In an article in The Cancer Letter entitled " Robert Cook-Deegan's Viewers' Guide To the Super Bowl of Gene Patent Cases ," Professor Robert Cook-Deegan of the Institute for Genome Sciences & Policy and Sanford School of Public Policy, Duke University provides his colleagues in the medical arts with an update on the progress of the Myriad case, ... (more)

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Patent / Trademark Law, Law, US News

JD Supra

USPTO Issues New Guidelines for Determining Subject Matter...

On March 4, 2014, the United States Patent and Trademark Office issued final guidance to the Examining Corps regarding patent eligibility of claims involving laws of nature, natural phenomena and natural products.

Comment?

Related Topix: Patent / Trademark Law, Law, USPTO, Biotech, Medicine, Healthcare Industry

Mon Mar 31, 2014

AmericanBankingNews.com

Myriad Genetics Given Average Recommendation of "Hold" by Analysts

Shares of Myriad Genetics have earned an average recommendation of "Hold" from the nineteen ratings firms that are presently covering the company, AnalystRatingsNetwork.com reports .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Genetics, Rules-Based Medicine, Myriad Pharmaceuticals

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••
•••